ICU Medical (NASDAQ:ICUI) Upgraded to Buy at Wall Street Zen

Wall Street Zen upgraded shares of ICU Medical (NASDAQ:ICUI) from a hold rating to a buy rating in a research report report published on Saturday morning.

A number of other research firms have also commented on ICUI. Piper Sandler cut their price objective on shares of ICU Medical from $178.00 to $163.00 and set an “overweight” rating for the company in a research report on Friday, April 17th. Jefferies Financial Group upgraded shares of ICU Medical to a “strong-buy” rating in a research report on Thursday. KeyCorp cut their price objective on shares of ICU Medical from $180.00 to $164.00 and set an “overweight” rating for the company in a research report on Monday, April 27th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of ICU Medical in a research report on Thursday, January 22nd. Two investment analysts have rated the stock with a Strong Buy rating, two have assigned a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, ICU Medical has a consensus rating of “Buy” and a consensus price target of $169.00.

ICU Medical Price Performance

Shares of NASDAQ:ICUI opened at $126.43 on Friday. The company has a quick ratio of 1.15, a current ratio of 2.39 and a debt-to-equity ratio of 0.60. The firm has a market capitalization of $3.16 billion, a PE ratio of 68.34, a P/E/G ratio of 1.82 and a beta of 0.74. ICU Medical has a twelve month low of $107.00 and a twelve month high of $160.29. The company has a 50-day moving average price of $128.93 and a two-hundred day moving average price of $138.35.

ICU Medical (NASDAQ:ICUI) last issued its earnings results on Thursday, May 7th. The medical instruments supplier reported $1.97 earnings per share for the quarter, topping analysts’ consensus estimates of $1.78 by $0.19. The firm had revenue of $525.77 million during the quarter, compared to analyst estimates of $520.65 million. ICU Medical had a net margin of 2.15% and a return on equity of 7.49%. The company’s quarterly revenue was down 12.3% on a year-over-year basis. During the same quarter last year, the business earned $1.72 earnings per share. ICU Medical has set its FY 2026 guidance at 7.750-8.450 EPS. Equities analysts forecast that ICU Medical will post 6.31 EPS for the current year.

Institutional Investors Weigh In On ICU Medical

Institutional investors and hedge funds have recently bought and sold shares of the stock. Bryce Point Capital LLC purchased a new stake in ICU Medical in the third quarter valued at approximately $586,000. Inscription Capital LLC raised its stake in ICU Medical by 407.9% in the third quarter. Inscription Capital LLC now owns 8,365 shares of the medical instruments supplier’s stock valued at $1,003,000 after purchasing an additional 6,718 shares in the last quarter. Federated Hermes Inc. raised its stake in ICU Medical by 56.5% in the third quarter. Federated Hermes Inc. now owns 290,292 shares of the medical instruments supplier’s stock valued at $34,823,000 after purchasing an additional 104,798 shares in the last quarter. Emerald Mutual Fund Advisers Trust purchased a new stake in ICU Medical in the third quarter valued at approximately $1,096,000. Finally, Schroder Investment Management Group raised its stake in shares of ICU Medical by 25.2% during the third quarter. Schroder Investment Management Group now owns 796,704 shares of the medical instruments supplier’s stock worth $93,246,000 after acquiring an additional 160,380 shares in the last quarter. 96.10% of the stock is owned by hedge funds and other institutional investors.

More ICU Medical News

Here are the key news stories impacting ICU Medical this week:

• Positive Sentiment: ICU Medical beat Q1 expectations on both earnings and revenue, reporting EPS of $1.97 versus the $1.78 consensus and revenue of $525.77 million versus $520.65 million expected. Article Title
• Positive Sentiment: The company also issued FY2026 EPS guidance of $7.75 to $8.45, slightly above the market’s expectation, which supports the view that profitability could improve further this year. Article Title
• Positive Sentiment: Jefferies upgraded ICU Medical to strong-buy, adding to investor optimism around the stock. Article Title
• Neutral Sentiment: Transcript and post-earnings coverage indicate that strength in infusion systems and consumables helped offset weakness in the Vital Care segment, suggesting mixed underlying trends within the business. Article Title
• Neutral Sentiment: Options activity showed surging implied volatility, signaling that traders expect a larger-than-usual move in the stock after earnings. Article Title
• Negative Sentiment: Revenue still fell 12.3% year over year, showing that ICU Medical is beating estimates but still facing pressure on top-line growth. Article Title

ICU Medical Company Profile

ICU Medical, Inc, together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy, vascular access, and vital care applications worldwide. Its infusion therapy products include needlefree products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; ChemoClave and ChemoLock closed system transfer devices, which are used to limit the escape of hazardous drugs or vapor concentrations, block the transfer of environmental contaminants into the system, and eliminates the risk of needlestick injury; Tego needle free connectors; Deltec GRIPPER non-coring needles for portal access; and ClearGuard, SwabCap, and SwabTip disinfection caps.